Anson Funds Management’s TransCode Therapeutics RNAZ Stock Holding History

Anson Funds Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-52,218	Closed	-$724K	–	146
2025 Q1	$724K	Buy	+52,218	New	+$6.69M	0.13%	95

Other funds holding RNAZ

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Anson Funds Management's RNAZ Position: Q2 2025 in Review

Anson Funds Management sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 52,218 shares — an estimated $724K sold.

Anson Funds Management first reported a position in RNAZ in Q1 2025 and held it in 1 quarter. The position peaked at $724K in Q1 2025. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

Anson Funds Management reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
Anson Funds Management sold 52,218 TransCode Therapeutics shares in Q2 2025, an estimated $724K.
Anson Funds Management first reported a position in TransCode Therapeutics in Q1 2025 and held it in 1 quarter.
Anson Funds Management's TransCode Therapeutics position peaked at $724K in Q1 2025.
9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Anson Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.